Jove
Visualize
お問い合わせ

関連する概念動画

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

618
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
618
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

452
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
452
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

502
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
502
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

659
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
659

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Respiratory Outbreak Mitigation With Point-of-Care Testing in Long-Term Care: A Randomized Clinical Trial.

JAMA internal medicine·2026
Same author

Laboratory Perspectives on Assay Selection and implementation of PlGF-Based Testing for Suspected Preterm Preeclampsia.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2026
Same author

Reflexing NT-proBNP for sFlt-1/PlGF Ratios That Fall into the Measurement Uncertainty for Preeclampsia Risk Classification.

Clinical chemistry·2026
Same author

Comparing Catheters to Fistulas in Older Patients Starting Hemodialysis (ACCESS HD).

Journal of the American Society of Nephrology : JASN·2026
Same author

FLOW Trial - The effect of fluoxetine combined with exercise on motor recovery after stroke: an RCT.

Archives of physical medicine and rehabilitation·2026
Same author

Design and rational of the the PRACTICAL-HERO trial: A randomized trial of higher and lower doses of heparin vs placebo for elective diagnostic coronary angiography.

American heart journal·2026
Same journal

A Bundle to Frame Guidelines and American Heart Association Statements.

Circulation·2026
Same journal

<i>Circulation</i> Editors and Editorial Board.

Circulation·2026
Same journal

A New <i>Circulation</i>, For You.

Circulation·2026
Same journal

Cardiovascular Risk Reduction With GLP-1 RA Drugs.

Circulation·2026
Same journal

Obesity, Severe Obesity, and Abdominal Obesity in US Youth and Adults From 1999 to 2023.

Circulation·2026
Same journal

Lipid Profile Testing and Interpretation.

Circulation·2026
関連記事をすべて見る
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

Updated: May 7, 2026

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

2.8K

皮膚経冠動脈介入 (SPIDER-PCI) の後の酵素放出を減少させるためのsPLA2阻害試験

Vladimír Džavík1, Shahar Lavi, Kevin Thorpe

  • 1Interventional Cardiology Program, Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada. vlad.dzavik@uhn.on.ca

Circulation
|November 25, 2010
PubMed
まとめ
この要約は機械生成です。

分泌性フォスフォリファーゼA(2) の阻害剤であるヴァレスプラディブは,皮膚経冠動脈介入後の心臓バイオマーカーの放出を減少させなかった. この研究では,PCI患者における筋硬化症の予防において,sPLA(2) 抑制の有意な利点が見つかりませんでした.

さらに関連する動画

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K
Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model
05:52

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model

Published on: November 4, 2021

2.6K

関連する実験動画

Last Updated: May 7, 2026

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

2.8K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K
Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model
05:52

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model

Published on: November 4, 2021

2.6K

科学分野:

  • 心臓病学 心臓病学
  • バイオケミストリー バイオケミストリー
  • 薬理学 薬理学とは

背景:

  • 分泌性フォスフォリパゼA(2) (sPLA(2) は,皮膚経冠動脈干渉 (PCI) の後の筋縮に関与しています.
  • sPLAを阻害すると,PCI後の心臓損傷の軽減に治療上の利点があるかもしれません.
  • ヴァレスプラディブ (Varespladib) は,sPLAを標的とする小分子阻害剤である.

研究 の 目的:

  • 選択性PCI後の術後の心臓バイオマーカーの放出を減らすためのヴァレスプラディブの有効性を調査する.
  • ヴァレスプラディブによるsPLA(2) 阻害がPCIに関連した筋縮を緩和するという仮説を検証する.

主な方法:

  • 選択PCIを受けた144人の安定した患者を対象としたII相,ランダム化,プラセボ対照試験です.
  • 患者は処置前の3〜5日と処置後の5日間,ヴァレスプラディブ (PO BID 500 mg) またはプラセボを投与されました.
  • 主要エンドポイント:PCI後の6-8時間または18-24時間後に,正常値の上限を超えるトロポニンIまたはクレアチンキナーゼ-MBの上昇.

主要な成果:

  • 主要エンドポイントは,ヴァレスプラディブ患者の75%とプラセボ患者の63% (P=0.14) で発生し,有意な減少を示さなかった.
  • トロポニンIの上昇 (3x ULN) は57%対50% (P=0.39) で,CK-MBの上昇 (2x ULN) は14%対3% (P=0.018) で観察されました.
  • ヴァレスプラディブはsPLA(2) の活性を著しく低下させましたが,高感度C反応性タンパク質のレベルには影響しませんでした.

結論:

  • 選択性PCIの3〜5日前にヴァレスプラディブを投与した結果,周辺手術性筋硬化症の減少は認められなかった.
  • バレスプラディブによるsPLAの抑制は,この患者集団において有意な効果を示さなかった.
  • PCIに関連する筋縮を予防するための他の治療戦略を探るため,さらなる研究が必要になる可能性があります.